Sareum Holdings plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sareum Holdings plc
Without disclosing data, Nimbus announced positive Phase IIb results for NDI-034858 in psoriasis. The company plans to initiate a Phase III trial next year.
The big pharma has returned the global commercial rights to Sareum’s lead program which GSK gained as part of its recently completed acquisition of Sierra Oncology, leaving Sareum scrambling for a new path forward.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.